Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
18 June 2013
Dr Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence…
OHE’s Devlin on Using the EQ-5D to Measure Patients’ Outcomes
11 June 2013
OHE’s Professor Nancy Devlin has researched, written and spoken widely on the use of the EQ-5D, and related measures, both in her capacity as the Director…
19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
4 June 2013
Since 1993, OHE has hosted an annual lecture given by an eminent economist or clinician on an important current issue. In 2012, Professor Sir Michael Rawlins…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” — those medicines that…
Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
7 May 2013
OHE has just released a research paper that describes an experimental study intended to test whether and how a multi-criteria decision analysis (MCDA) approach can be…
NICE Decisions: Exploring the Influence of Cost-Effectiveness and Other Factors
30 April 2013
OHE presents a series of lunchtime seminars throughout the year. The most recent seminar, held in late April, considered the influence of cost-effectiveness and other factors…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
Advances in science and technology are producing more and better means for diagnosing disease, matching patients to the best therapies, and tracking the progress of treatment.…
Performance-Based Risk Sharing in Health Care: Current Status
17 April 2013
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on…
Lunchtime Seminar: Capturing Preferences about Treatment at the End of Life
9 April 2013
OHE’s Koonal Shah is a co-investigator in research intended to define public preferences about allocating health care resources to patients who are at the end of…